Modality
Degrader
MOA
PI3Ki
Target
SGLT2
Pathway
Cell Cycle
SchizophreniaMesoRSV
Development Pipeline
Preclinical
Mar 2019
→ Jan 2030
PreclinicalCurrent
NCT04020868
1,764 pts·Meso
2019-03→2027-09·Completed
NCT04775695
152 pts·Schizophrenia
2021-12→2030-01·Terminated
1,916 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-261.5y awayInterim· Meso
2030-01-133.8y awayInterim· Schizophrenia
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Complet…
Preclinical
Termina…
Catalysts
Interim
2027-09-26 · 1.5y away
Meso
Interim
2030-01-13 · 3.8y away
Schizophrenia
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04020868 | Preclinical | Meso | Completed | 1764 | Biomarker |
| NCT04775695 | Preclinical | Schizophrenia | Terminated | 152 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 |